A Trial of SHR-7367 in Subjects With Advanced Solid Tumors

Inclusion criteria

• Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;
• Male or female aged ≥18 years and ≤75 years at the time of signing the ICF;
• Histopathologically or cytologically documented advanced or metastatic malignancies;
• At least 1 measurable lesion conforming to RECIST 1.1 criteria;
• An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
• Female and male patients of reproductive potential must agree to use highly effective contraception.

Exclusion criteria

• Any immunostimulants administered within 4 weeks;
• Systemic anti-tumor therapy within 4 weeks;
• Any investigational cancer therapy administered within 4 weeks;
• Surgical procedures requiring general anesthesia within 4 weeks;
• History of autoimmune diseases;
• History of immunodeficiency;
• Severe infections within 2 weeks prior to the first study treatment;
• Clinically significant cardiovascular condition;
• Prior malignancy (other than current malignant tumor) within 5 ears before the first dose of study treatment;
• Known history of serious allergic reactions to the investigational product or its main ingredients.